News
Actemra Approved for Treatment of Hospitalized COVID-19 Patients
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
High-dose inhaled nitric oxide linked to more days free from oxygen supplementation, shorter ICU and hospital length of stay
Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity
Rates of severe disease low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies
No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen